読み込み中
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
前日終値
$4.79
+$0.13 · +2.79%
日中の時刻はETです。市場データは遅延する場合があります。
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
日中レンジ
現在 $4.79
52週レンジ
現在 $4.79
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
37
割高
センチメント
41
まちまち
リスク
54
やや高いリスク
モメンタム
62
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
日中レンジ
現在 $4.79
52週レンジ
現在 $4.79
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1866.6万 USD | 2639.1万 USD | 3416.4万 USD | 5907.7万 USD | 3474.8万 USD |
| 売上原価 | 2205.7万 USD | — | — | — | — |
| 粗利益 | −339.1万 USD | 2639.1万 USD | 3416.4万 USD | 5907.7万 USD | 3474.8万 USD |
| 研究開発 | 4775.4万 USD | 5511万 USD | 5652.5万 USD | 4836.4万 USD | 3923.2万 USD |
| 販売・一般管理 | 2921.5万 USD | 3074.1万 USD | 3331.3万 USD | 2490.3万 USD | 1694.7万 USD |
| 営業費用 | 6812.7万 USD | 1.01億 USD | 1.04億 USD | 8572.5万 USD | 7035.7万 USD |
| 受取利息 | 266万 USD | 310.6万 USD | 505.5万 USD | 58.7万 USD | — |
| 支払利息 | — | — | — | — | 7000 USD |
| 減価償却費と償却費 | 2175.4万 USD | 2358.3万 USD | 1949.7万 USD | 1824.9万 USD | 1625.2万 USD |
| 営業利益 | −7151.8万 USD | −7450.2万 USD | −6941.9万 USD | −2664.8万 USD | −3560.9万 USD |
| 純利益 | −6477.9万 USD | −6203.3万 USD | −5061.9万 USD | −2233.4万 USD | −2704.2万 USD |
会社概要が更新されました 2026年10月11日.
この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM1355.13万0.02%787.4億 USD0.19%$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI1042.32万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF611.98万0.01%954億 USD0.05%$235+0.80%
iShares Biotechnology ETFIBB433.68万0.04%108.2億 USD0.44%$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA280.48万0.01%218.24億 USD0.03%$32.79+0.40%
Vanguard Russell 2000 ETFVTWO277.02万0.02%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC161.88万0.12%13.17億 USD0.60%$183+0.11%
Dimensional - US Small Cap ETFDFAS152.71万0.00%338.69億 USD0.31%$78.35+0.32%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
